Physician profile
Benjamin Solomon
NPI 1952538209
$2,458.97
in general payments reported to CMS, 2019-2025
28 companies · $804 in 2025
The $804 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $77.94 · 2021: $199 · 2022: $458 · 2023: $291 · 2024: $324 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Education: $98.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.81 |
| Education | $98.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $267.06 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $261.40 | 2021-2025 | Acessa Provu System, Aptima |
| Abbvie INC. | $237.23 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Sage Therapeutics, LLC | $216.11 | 2021-2025 | Zurzuvae |
| Myovant Sciences INC. | $189.57 | 2021-2022 | |
| Amgen INC. | $140.49 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $130.82 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.46 | 2019-2025 | |
| Exeltis, USA INC. | $104.96 | 2023-2025 | Slynd |
| Organon LLC | $91.90 | 2024-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $80.77 | 2023-2025 | Myfembree |
| Amag Pharmaceuticals, INC. | $79.12 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $76.73 | 2024-2025 | |
| Aspira Women'S Health INC | $73.85 | 2022 | |
| Renovia INC | $58.43 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $54.54 | 2022 | |
| Supernus Pharmaceuticals, INC. | $44.66 | 2025 | Qelbree |
| Shield Therapeutics INC | $43.24 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $29.25 | 2024 | Cologuard Collection Kit |
| Millicent US INC | $27.29 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Therapeuticsmd, INC. | $24.09 | 2019 | |
| Coopersurgical, INC. | $19.24 | 2019 | |
| Lilly USA, LLC | $18.16 | 2025 | Zepbound, Mounjaro |
| Convatec INC. | $15.41 | 2025 | |
| Merck Sharp & Dohme LLC | $13.24 | 2021 | |
| Avion Pharmaceuticals | $11.97 | 2019 | |
| Allergan, INC. | $11.40 | 2019 | |
| Meditrina | $9.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.